Literature DB >> 11712939

Oculopharyngeal muscular dystrophy in Hispanic New Mexicans.

M W Becher1, L Morrison, L E Davis, W C Maki, M K King, J M Bicknell, B L Reinert, C Bartolo, D G Bear.   

Abstract

CONTEXT: Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy caused by polyalanine triplet repeat expansion in the gene for poly(A) binding protein 2 (PABP2) and is found in isolated cohorts throughout the world. We have observed numerous cases of OPMD in New Mexico.
OBJECTIVE: To characterize the clinical, genetic, and demographic features of the OPMD population in New Mexico. DESIGN, SETTING, AND PARTICIPANTS: Cohort study with analysis of outpatient clinic medical records from 1965 to 2001 at the University of New Mexico Hospital and the New Mexico VA Health Care System in Albuquerque, which serve the entire state. MAIN OUTCOME MEASURES: Clinical phenotype, supplemented with genetic confirmation (n = 10 patients) and in-depth clinical evaluations (n = 49 patients).
RESULTS: We identified 216 cases of OPMD (99 women and 117 men) from 39 kindreds of New Mexicans spanning up to 4 generations. All patients were Hispanic, and the majority of probands came from northern New Mexico. In patients who had both ocular and pharyngeal muscle weakness, ptosis was just as likely to occur before or concurrent with dysphagia. Proximal limb muscle weakness and gait abnormalities were common and occurred later than ocular or pharyngeal weakness. The clinical expression of OPMD caused marked debility, although life-table analysis showed no decrease in life expectancy compared with unaffected family members (P =.81). Ten individuals from different kindreds were found to have an identical polyalanine triplet repeat expansion ([GCG](9)) in the PABP2 gene.
CONCLUSIONS: Individuals in this cohort had clinical and genetic characteristics of classic OPMD. Longevity was not affected, but patients experienced considerable morbidity. The origin of the PABP2 mutation in New Mexican OPMD patients is unclear, although the geographic and genetic isolation of northern New Mexicans with a long ancestry in this region may have contributed to the development of this cohort. This disease cohort represents a large and previously unrecognized health care issue in the state of New Mexico and should serve to raise the awareness of this disorder among clinicians who treat Hispanics in the Southwest and throughout the United States.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712939     DOI: 10.1001/jama.286.19.2437

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

Review 1.  [Cardiac manifestations of muscular dystrophies].

Authors:  A Perrot; S Spuler; C Geier; R Dietz; K J Osterziel
Journal:  Z Kardiol       Date:  2005-05

2.  Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.

Authors:  Sarah Youssof; Ronald M Schrader; Carol Romero-Clark; Gulmohor Roy; Michael Spafford
Journal:  Muscle Nerve       Date:  2014-02-25       Impact factor: 3.217

3.  Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: a retrospective study with implications for trial design.

Authors:  Sarah Youssof; Ronald Schrader; David Bear; Leslie Morrison
Journal:  Neuromuscul Disord       Date:  2014-11-20       Impact factor: 4.296

4.  The NIH Office of Rare Diseases Research patient registry Standard: a report from the University of New Mexico's Oculopharyngeal Muscular Dystrophy Patient Registry.

Authors:  Shamsi Daneshvari; Sarah Youssof; Philip J Kroth
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

5.  Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis.

Authors:  Björn Oskarsson; Steven P Ringel
Journal:  Neuromuscul Disord       Date:  2013-03-01       Impact factor: 4.296

Review 6.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

7.  Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1.

Authors:  Yves B Beaulieu; Claudia L Kleinman; Anne-Marie Landry-Voyer; Jacek Majewski; François Bachand
Journal:  PLoS Genet       Date:  2012-11-15       Impact factor: 5.917

8.  A GCG expansion (GCG)₁₁ in polyadenylate-binding protein nuclear 1 gene caused oculopharyngeal muscular dystrophy in a Chinese family.

Authors:  Juan Ye; Huina Zhang; Yandan Zhou; Han Wu; Changjun Wang; Xin Shi
Journal:  Mol Vis       Date:  2011-05-25       Impact factor: 2.367

9.  Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.

Authors:  Pascale Richard; Capucine Trollet; Tanya Stojkovic; Alix de Becdelievre; Sophie Perie; Jean Pouget; Bruno Eymard
Journal:  Neurology       Date:  2016-12-23       Impact factor: 9.910

10.  Cross-cultural adaptation of the SWAL-QOL and the Sydney Swallow Questionnaire (SSQ) into French-Canadian and preliminary assessment for their use in an oculopharyngeal muscular dystrophy (OPMD) population.

Authors:  Claudia Côté; Julie Fortin; Bernard Brais; Sarah Youssof; Cynthia Gagnon
Journal:  Qual Life Res       Date:  2021-07-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.